Switzerland-based Ferring Pharmaceuticals has appointed Dominic Moorhead as its new executive vice president and chief financial officer.
Following a three-month transition period, Moorhead will assume full responsibility for the Finance, Corporate Information Systems and International Audit functions.
With over 30 years experience in the life sciences industry, Moorhead has held a number of senior roles such as strategic advisor to executives and investors in biotech, global financial controller for Takeda Pharmaceuticals, and CFO of the international business following the acquisition of Nycomed.
Prior to this, he served Hoffman- La Roche (Roche) where he was CFO of its pharma division for nine years.
Michel Pettigrew, president of the executive board and chief operating officer of Ferring, said: “His extensive experience and perspectives in finance, business and strategic development in the pharmaceutical sector make him a great fit for Ferring as we continue on our strong growth path.”
Moorhead succeeds Peter Wilden who will still continue to represent Ferring on a number of additional boards.